by GlobeNewsWire | Apr 18, 2016 | Globe Newswire
NEW YORK, April 18, 2016 (GLOBE NEWSWIRE) — Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage biotechnology company developing novel therapies for ophthalmic diseases, today announced that the first patient has been enrolled in the first Phase III...
by GlobeNewsWire | Mar 29, 2016 | Globe Newswire
NEW YORK, March 29, 2016 (GLOBE NEWSWIRE) — Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage biotechnology company developing novel therapies for ophthalmic diseases, today announced that it has reached an agreement on the Special Protocol Assessment...
by GlobeNewsWire | Mar 2, 2016 | Globe Newswire
NEW YORK, March 02, 2016 (GLOBE NEWSWIRE) — Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive Officer, will present a corporate overview and business update at the...
by GlobeNewsWire | Dec 10, 2015 | Globe Newswire
OHR-102 Phase 3 Program in Wet-AMD to be Initiated Upon Completion of SPA; Enroll Patients in Q1 2016 Conference Call and Webcast with Slides, Today at 5:00pm Eastern Time NEW YORK, Dec. 10, 2015 (GLOBE NEWSWIRE) — Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an...
by GlobeNewsWire | Nov 16, 2015 | Globe Newswire
Occult CNV Size in Wet-AMD is Predictive of Success of OHR-102 Combination Therapy Results Drive Patient Selection and Design for Phase 3 Program NEW YORK, Nov. 16, 2015 (GLOBE NEWSWIRE) — Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and...